← ANALYST RATINGS · TIPRANKS
Ironwood Pharma (IRWD): analyst forecast and price target
Analyst consensus
0 Buy0 Hold0 Sell
Ratings of 0 analysts in the last 3 months12-month forecast
Based on 0 price targets given in the last 3 months, the average target is —, the highest —, the lowest —. The average is — from the last price of $3.50.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $4.00 | Hold | +14.3% | Downgrade | 16.10.26on TipRanks 18:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $4.00 | Hold | +14.3% | Downgrade | 16.10.26on TipRanks 18:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $3.50 → $4.00+14.3% | Hold | +14.3% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $4.00 → $4.50+12.5% | Buy | +28.6% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 | Hold | +14.3% | Downgrade | 16.10.26on TipRanks 18:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $4.50 → $4.00−11.1% | Hold | +14.3% | Reiterated | 03.10.26on TipRanks Oct 2 23:06 | — | |
| Chase Knickerbocker★★★★★★★★★★#75 · hits 59% · avg +36.2% | Craig-Hallum | — | Buy | — | Reiterated | 14.07.26on TipRanks Jul 15 16:35 | −5.8%next day +0.1% · 5 days −1.3% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $5.00 | Hold | +42.9% | Reiterated | 05.05.26on TipRanks May 6 01:50 | +0.9%next day +2.0% · 5 days −14.4% | ↗ |
| Jason Butler★★★★★★★★★★#412 · hits 51% · avg +18.3% | Citizens JMP | $8.00 → $10.00+25.0% | Buy | +185.7% | Reiterated | 26.02.26on TipRanks 06:10 | +9.5%next day −6.1% · 5 days +0.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Ironwood Pharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 1 | 2 | 1 | 1 | 0 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.32 (from $0.30 to $0.35). Last quarter: $0.31.
Sales
Next quarter’s sales estimate — $120M (from $115M to $122M). Last quarter: $113M.
Best top-analyst consensus in the sector · Healthcare
About Ironwood Pharma
- CEO: Thomas A. McCourt
- Employees: 100
- 100 Summer Street, Boston, MA, 02110, US
- www.ironwoodpharma.com
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
Data from the stock’s TipRanks forecast page, read 191 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗